Literature DB >> 16237069

Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts.

Ran Tao1, Liqing Wang, Rongxiang Han, Tao Wang, Qunrui Ye, Takasu Honjo, Theresa L Murphy, Kenneth M Murphy, Wayne W Hancock.   

Abstract

Although fully MHC-mismatched murine cardiac allografts are rapidly rejected, allografts mismatched at only MHC class I or class II alleles survive long term; the immunologic basis for the long-term survival of MHC class I- or II-mismatched allografts is unknown. We examined the roles of two recently described inhibitory receptors, B and T lymphocyte attenuator (BTLA) and programmed death-1 (PD-1), in the survival of partially or fully MHC-mismatched allografts using gene-deficient recipients as well as through use of blocking mAbs in wild-type hosts. Partially MHC-mismatched allografts showed strong induction of BTLA, but not PD-1 mRNA and survived long term in wild-type recipients, whereas targeting of BTLA or its ligand, herpesvirus entry mediator, but not PD-1, prompted their rapid rejection. By contrast, fully MHC-mismatched cardiac allografts were acutely rejected in wild-type recipients despite the induction of both BTLA and PD-1. Targeting of PD-1 in several fully MHC-mismatched models accelerated rejection, whereas targeting of BTLA unexpectedly enhanced PD-1 induction by alloreactive CD4 and CD8 T cells and prolonged allograft survival. In vitro studies using allogeneic dendritic cells and T cells showed that at low levels of T cell activation, BTLA expression was primarily induced, but that with increasing degrees of T cell activation, the expression of PD-1 was strongly up-regulated. These data suggest that BTLA and PD-1 exert distinct inhibitory actions in vivo, with the BTLA/herpesvirus entry mediator pathway appearing to dominate in regulating responses against a restricted degree of allogeneic mismatch.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237069     DOI: 10.4049/jimmunol.175.9.5774

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

Review 1.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

2.  Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus.

Authors:  M Zhang; K Howard; A Winters; S Steavenson; S Anderson; S Smelt; G Doellgast; C Sheelo; J Stevens; H Kim; A Hamburger; A Sein; D J Caughey; F Lee; H Hsu; G Siu; F R Byrne
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

Review 3.  LIGHT-related molecular network in the regulation of innate and adaptive immunity.

Authors:  Yanhui Xu; Koji Tamada; Lieping Chen
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 4.  Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners.

Authors:  Marcos W Steinberg; Jr-Wen Shui; Carl F Ware; Mitchell Kronenberg
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

5.  Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease.

Authors:  Yanhui Xu; Andrew S Flies; Dallas B Flies; Gefeng Zhu; Sudarshan Anand; Sarah J Flies; Haiying Xu; Robert A Anders; Wayne W Hancock; Lieping Chen; Koji Tamada
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

Review 6.  The TNF receptor and Ig superfamily members form an integrated signaling circuit controlling dendritic cell homeostasis.

Authors:  Carl De Trez; Carl F Ware
Journal:  Cytokine Growth Factor Rev       Date:  2008-06-03       Impact factor: 7.638

7.  NFATc1 regulates PD-1 expression upon T cell activation.

Authors:  Kenneth J Oestreich; Hyesuk Yoon; Rafi Ahmed; Jeremy M Boss
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

8.  Vstm3 is a member of the CD28 family and an important modulator of T-cell function.

Authors:  Steven D Levin; David W Taft; Cameron S Brandt; Christoph Bucher; Edward D Howard; Eric M Chadwick; Janet Johnston; Angela Hammond; Kristen Bontadelli; Daniel Ardourel; LuAnn Hebb; Anitra Wolf; Thomas R Bukowski; Mark W Rixon; Joseph L Kuijper; Craig D Ostrander; James W West; Janine Bilsborough; Brian Fox; Zeren Gao; Wenfeng Xu; Fred Ramsdell; Bruce R Blazar; Katherine E Lewis
Journal:  Eur J Immunol       Date:  2011-03-18       Impact factor: 5.532

9.  Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator.

Authors:  Yoshihiro Oya; Norihiko Watanabe; Takayoshi Owada; Mie Oki; Koichi Hirose; Akira Suto; Shin-Ichiro Kagami; Hiroshi Nakajima; Takashi Kishimoto; Itsuo Iwamoto; Theresa L Murphy; Kenneth M Murphy; Yasushi Saito
Journal:  Arthritis Rheum       Date:  2008-08

10.  The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept.

Authors:  Renaud Snanoudj; Carlos Frangié; Benjamin Deroure; Hélène François; Caroline Créput; Séverine Beaudreuil; Antoine Dürrbach; Bernard Charpentier
Journal:  Biologics       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.